KR102254957B1 - 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) - Google Patents

골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) Download PDF

Info

Publication number
KR102254957B1
KR102254957B1 KR1020167015759A KR20167015759A KR102254957B1 KR 102254957 B1 KR102254957 B1 KR 102254957B1 KR 1020167015759 A KR1020167015759 A KR 1020167015759A KR 20167015759 A KR20167015759 A KR 20167015759A KR 102254957 B1 KR102254957 B1 KR 102254957B1
Authority
KR
South Korea
Prior art keywords
gastrin
bone
hypergastrinemia
cells
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167015759A
Other languages
English (en)
Korean (ko)
Other versions
KR20160088891A (ko
Inventor
마크 키드
얼빈 마크 모들린
Original Assignee
씨엘 바이오사이언시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102254957(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 씨엘 바이오사이언시즈 엘엘씨 filed Critical 씨엘 바이오사이언시즈 엘엘씨
Publication of KR20160088891A publication Critical patent/KR20160088891A/ko
Application granted granted Critical
Publication of KR102254957B1 publication Critical patent/KR102254957B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167015759A 2013-11-22 2014-11-21 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) Active KR102254957B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907980P 2013-11-22 2013-11-22
US61/907,980 2013-11-22
PCT/US2014/066832 WO2015077572A1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (2)

Publication Number Publication Date
KR20160088891A KR20160088891A (ko) 2016-07-26
KR102254957B1 true KR102254957B1 (ko) 2021-05-25

Family

ID=52118000

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015759A Active KR102254957B1 (ko) 2013-11-22 2014-11-21 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드)

Country Status (14)

Country Link
US (1) US10709714B2 (https=)
EP (1) EP3071206B1 (https=)
JP (1) JP6502939B2 (https=)
KR (1) KR102254957B1 (https=)
CN (1) CN106163527A (https=)
AU (1) AU2014352875B2 (https=)
BR (1) BR112016011727A2 (https=)
CA (1) CA2929858C (https=)
DK (1) DK3071206T3 (https=)
ES (1) ES2870538T3 (https=)
MX (1) MX2016006657A (https=)
PL (1) PL3071206T3 (https=)
RU (1) RU2693484C1 (https=)
WO (1) WO2015077572A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN115770266B (zh) * 2023-01-30 2023-05-09 云南中医药大学 一种用于治疗绝经后骨质疏松的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012817A1 (en) 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
WO2005007107A2 (en) 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992437A (en) 1987-12-22 1991-02-12 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their pharmaceutical use
DK0411668T4 (da) 1989-08-04 1999-08-09 Merck Sharp & Dohme Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
WO1992011246A1 (en) 1990-12-25 1992-07-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzodiazepine derivative
WO1993000897A1 (en) 1991-07-12 1993-01-21 Warner-Lambert Company Cholecystokinin antagonists useful in the treatment of panic attacks
EP0638560A4 (en) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
IL104853A (en) 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
TW281669B (https=) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
GB2282595A (en) 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IT1261255B (it) 1993-09-09 1996-05-09 Rotta Research Lab Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
JP4442930B2 (ja) 1995-12-11 2010-03-31 タフツ メディカル センター インコーポレイテッド ペプチドホルモンレセプターリガンドに関するアッセイ法およびその使用
US5922883A (en) 1996-04-03 1999-07-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
HUP0002760A3 (en) 1997-05-12 2003-03-28 Aphton Corp Woodland Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
EP1076561B1 (en) 1998-05-15 2005-03-30 Aphton Corporation Combination therapy for the treatment of tumors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
BR0015315A (pt) 1999-11-05 2002-06-25 Sod Conseils Rech Applic Compostos, medicamentos, composições farmacêuticas, utilização de compostos e produtos industriais
AU3003701A (en) 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
CA2404852A1 (en) 2000-04-10 2001-10-18 Timothy C. Wang Diagnosis and treatment of gastrointestinal disease
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
CA2441228A1 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
JPWO2002087620A1 (ja) 2001-04-27 2004-08-12 中外製薬株式会社 軟骨形成促進剤
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20040138207A1 (en) 2001-05-11 2004-07-15 Mayumi Yamano Antitumor agents
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
EP1443934B1 (en) 2001-11-13 2005-04-20 James Black Foundation Limited Benzotriazepines as gastrin and cholecystokinin receptor ligands
US20050176796A1 (en) 2002-02-19 2005-08-11 D'alessio Roberto Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
JP2006528241A (ja) 2003-03-28 2006-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾ［１，２，５］チアジアゾール化合物
US7524837B2 (en) 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
UA84025C2 (en) 2003-08-08 2008-09-10 Янссен Фармацевтика Н.В. Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en) 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
JP2008514608A (ja) 2004-09-24 2008-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルホンアミド化合物
WO2006044352A2 (en) 2004-10-12 2006-04-27 Janssen Pharmaceutica N.V. Canine cholecystokinin 1 receptor materials and their use
WO2006049941A2 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
JP2008519078A (ja) 2004-11-04 2008-06-05 ニューロゲン コーポレイション Ｃｂ１拮抗薬としてのアリールアルキル尿素類
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
AU2005315303A1 (en) 2004-12-17 2006-06-22 Pfizer Inc. Chromane derivatives useful as acid pump antagonists
CA2594482C (en) 2005-01-19 2013-10-01 Zeria Pharmaceutical Co., Ltd. Antitumor agent
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
US8053413B2 (en) 2005-06-06 2011-11-08 The Board Of Trustees Of The University Of Illinois Methods for treating sleep disorders by cholecystokinin (CCK) receptor B antagonists
DE602006009105D1 (de) 2005-06-14 2009-10-22 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
DE602005013372D1 (de) 2005-07-29 2009-04-30 Rottapharm Spa Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten
WO2007026218A2 (en) 2005-09-01 2007-03-08 Pfizer Japan Inc. Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
KR101088247B1 (ko) 2005-12-19 2011-11-30 라퀄리아 파마 인코포레이티드 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
WO2007072142A2 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazole-5-carboxamide derivatives
EP1996589A1 (en) 2006-03-17 2008-12-03 RaQualia Pharma Inc Chromane derivatives
EP2004631A1 (en) 2006-04-12 2008-12-24 Merck Patent GmbH N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
FR2901473B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
FR2901472B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
JP5140080B2 (ja) 2006-09-21 2013-02-06 ラクオリア創薬株式会社 選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2008124518A1 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
RU2379043C2 (ru) * 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
WO2009020768A1 (en) 2007-08-07 2009-02-12 President And Fellows Of Harvard College Targeting the oncoprotein nucleophosmin
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
TW201102371A (en) 2009-03-31 2011-01-16 Zeria Pharm Co Ltd Method for manufacturing benzodiazepine derivative
KR101605063B1 (ko) 2009-07-09 2016-03-21 라퀄리아 파마 인코포레이티드 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제
US20130029967A1 (en) 2009-09-24 2013-01-31 Centro Nacional De Investigaciones Oncologicas (Cnio) Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors
IL266563B (en) 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
AU2010319298B2 (en) 2009-11-13 2015-11-05 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
KR20130069640A (ko) 2010-04-23 2013-06-26 키네타, 인크. 항-바이러스 화합물
WO2012021837A2 (en) 2010-08-12 2012-02-16 Senomyx, Inc. Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
EP2640379A4 (en) 2010-11-18 2014-08-13 Pier Pharmaceuticals LOW DOSED CANNABINOIDARY MEDICINES
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
CN104039801B (zh) 2011-11-07 2017-05-10 麻省理工学院 用于z选择性烯烃复分解的钨氧代亚烷基络合物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012817A1 (en) 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
WO2005007107A2 (en) 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer

Also Published As

Publication number Publication date
BR112016011727A2 (pt) 2017-08-08
US10709714B2 (en) 2020-07-14
US20150148339A1 (en) 2015-05-28
ES2870538T3 (es) 2021-10-27
AU2014352875A1 (en) 2016-05-26
PL3071206T3 (pl) 2022-01-17
JP6502939B2 (ja) 2019-04-17
EP3071206A1 (en) 2016-09-28
MX2016006657A (es) 2016-10-12
CA2929858C (en) 2022-03-29
KR20160088891A (ko) 2016-07-26
CN106163527A (zh) 2016-11-23
EP3071206B1 (en) 2021-02-17
RU2693484C1 (ru) 2019-07-03
RU2016124538A (ru) 2017-12-27
JP2016538295A (ja) 2016-12-08
AU2014352875A8 (en) 2016-06-30
AU2014352875B2 (en) 2019-10-24
DK3071206T3 (da) 2021-05-25
CA2929858A1 (en) 2015-05-28
WO2015077572A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
Lesclous et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?
Salari Sharif et al. Current, new and future treatments of osteoporosis
Makhoul et al. The best of both worlds—managing the cancer, saving the bone
KR102254957B1 (ko) 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드)
Di Bella et al. Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report
US11135212B2 (en) Method for treating osteoporosis, osteopenia or low bone mineral density
Abo-Elenin et al. An overview of osteoporosis and possible treatment approaches
Mohanty et al. Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review: S. Mohanty et al.
Zwolak et al. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone
Kim et al. Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration
Vashghani Farahani et al. The effects of pentoxifylline adminstration on fracture healing in a postmenopausal osteoporotic rat model
McDonald et al. Bisphosphonate treatment and fracture repair
Goel et al. 9-Demethoxy-medicarpin promotes peak bone mass achievement and has bone conserving effect in ovariectomized mice: Positively regulates osteoblast functions and suppresses osteoclastogenesis
Liu et al. An evodiamine derivative inhibits osteoclast differentiation and protects against OVX‐induced bone loss in mice
HK1230487A1 (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Abo-Rayah et al. Forskolin Could Protect Against Flutamide-Induced Osteoporosis By Modulation of Serum Osteocalcin and Sclerostin In Rats
US9273006B2 (en) Anabolic compounds for treating and preventing bone loss diseases
Ballon-Landa et al. Management of bone complications in patients with genitourinary malignancies
Canuas Landero Defining how oestrogen influences the anti-tumour effects of adjuvant bisphosphonates using in vivo models of breast cancer
Xiong et al. Quercetin alleviates osteoporosis in rat mandibles induced by ovariectomy through modulation of autophagy and inhibition of NLRP3 pathway
Fasipe et al. Osteoporosis Now and in the Future: The Role of Newer Emerging Agents in the Management of Osteoporotic Bone Diseases–A Review
Hershman et al. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer
Peyruchaud et al. Lysophosphatidic Acid (LPA) Signaling and Bone Cancer
Loss World Journal of Surgical, Medical and Radiation Oncology
TOBIAS et al. Emerging therapies for osteoporosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5